Matrix metalloproteinase-3 serum levels in schizophrenic patients.

IF 2.9 4区医学 Q2 PSYCHIATRY

International Journal of Psychiatry in Clinical Practice Pub Date : 2023-03-01 DOI:10.1080/13651501.2022.2057332

Michal Ordak, Malgorzata Libman-Sokolowska, Tadeusz Nasierowski, Bogna Badyra, Leszek Kaczmarek, Elzbieta Muszynska, Magdalena Bujalska-Zadrozny

{"title":"Matrix metalloproteinase-3 serum levels in schizophrenic patients.","authors":"Michal Ordak, Malgorzata Libman-Sokolowska, Tadeusz Nasierowski, Bogna Badyra, Leszek Kaczmarek, Elzbieta Muszynska, Magdalena Bujalska-Zadrozny","doi":"10.1080/13651501.2022.2057332","DOIUrl":null,"url":null,"abstract":"Objectives: It has been reported that matrix metalloproteinase, MMP-3 may play a significant role in the pathophysiology of mental disorders. However, there are no data on the level of MMP-3 in people suffering from schizophrenia, or its influence on the mental state of these people. The aim of this study was to investigate the effect of an antipsychotic treatment on the blood levels of MMP-3, as well as investigating its relationship with insight into schizophrenia.Methods: Thirty people with schizophrenia were included in the study. The concentration of MMP-3 in the blood serum was assessed using enzyme-linked immunosorbent assay. Insight into the disease was assessed using the Beck Cognitive Insight Scale.Results: The antipsychotic treatment applied decreased the levels of MMP-3 in patients with schizophrenia (p = 0.005), however, the statistically significant interaction (p = 0.02) indicates that the decrease only concerned men. There was also a statistically significant correlation between the level of MMP-3 and insight into the disease (p = 0.02).Conclusion: MMP-3 may be associated with gender, treatment and symptoms in schizophrenic patients.KEY POINTSMMP3 could be used as a potential biomarker for schizophrenia.The level of MMP-3 decreased due to the applied antipsychotic treatment.The higher the level of MMP-3 in a group of people with schizophrenia, the better insight into their disease.","PeriodicalId":14351,"journal":{"name":"International Journal of Psychiatry in Clinical Practice","volume":"27 1","pages":"1-7"},"PeriodicalIF":2.9000,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Psychiatry in Clinical Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13651501.2022.2057332","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PSYCHIATRY","Score":null,"Total":0}

引用次数: 1

Abstract

Objectives: It has been reported that matrix metalloproteinase, MMP-3 may play a significant role in the pathophysiology of mental disorders. However, there are no data on the level of MMP-3 in people suffering from schizophrenia, or its influence on the mental state of these people. The aim of this study was to investigate the effect of an antipsychotic treatment on the blood levels of MMP-3, as well as investigating its relationship with insight into schizophrenia.

Methods: Thirty people with schizophrenia were included in the study. The concentration of MMP-3 in the blood serum was assessed using enzyme-linked immunosorbent assay. Insight into the disease was assessed using the Beck Cognitive Insight Scale.

Results: The antipsychotic treatment applied decreased the levels of MMP-3 in patients with schizophrenia (p = 0.005), however, the statistically significant interaction (p = 0.02) indicates that the decrease only concerned men. There was also a statistically significant correlation between the level of MMP-3 and insight into the disease (p = 0.02).

Conclusion: MMP-3 may be associated with gender, treatment and symptoms in schizophrenic patients.KEY POINTSMMP3 could be used as a potential biomarker for schizophrenia.The level of MMP-3 decreased due to the applied antipsychotic treatment.The higher the level of MMP-3 in a group of people with schizophrenia, the better insight into their disease.

查看原文本刊更多论文

精神分裂症患者血清基质金属蛋白酶-3水平。

目的:基质金属蛋白酶MMP-3可能在精神障碍的病理生理中起重要作用。然而，目前还没有关于精神分裂症患者体内MMP-3水平的数据，也没有关于其对这些人精神状态影响的数据。本研究的目的是调查抗精神病药物对血液中MMP-3水平的影响，以及调查其与精神分裂症的关系。方法:30例精神分裂症患者纳入研究。采用酶联免疫吸附法测定血清中MMP-3的浓度。对疾病的洞察力使用贝克认知洞察力量表进行评估。结果:抗精神病药物降低了精神分裂症患者的MMP-3水平(p = 0.005)，然而，统计学上显著的相互作用(p = 0.02)表明这种降低只涉及男性。MMP-3水平与疾病洞察力之间也有统计学意义的相关性(p = 0.02)。结论:MMP-3可能与精神分裂症患者的性别、治疗和症状有关。smmp3可以作为精神分裂症的潜在生物标志物。抗精神病药物的应用降低了MMP-3的水平。精神分裂症患者体内MMP-3水平越高，就越能更好地了解他们的疾病。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Psychiatry in Clinical Practice 医学-精神病学

CiteScore

6.00

自引率

3.30%

发文量

审稿时长

>12 weeks

期刊介绍： International Journal of Psychiatry in Clinical Practice provides an international forum for communication among health professionals with clinical, academic and research interests in psychiatry. The journal gives particular emphasis to papers that integrate the findings of academic research into realities of clinical practice. Focus on the practical aspects of managing and treating patients. Essential reading for the busy psychiatrist, trainee and interested physician. Includes original research papers, comprehensive review articles and short communications. Key words: Psychiatry, Neuropsychopharmacology, Mental health, Neuropsychiatry, Clinical Neurophysiology, Psychophysiology, Psychotherapy, Addiction, Schizophrenia, Depression, Bipolar Disorders and Anxiety.